R&D Paving the road to functionally active antibody drugs Antibody drugs have reshaped how we treat diseases.
Oncology Understanding the tumour micro-environment – the pharmaphoru... As our understanding of oncology has increased, it’s become clear that each cancer consists of much more than just the tumour cell – a whole ecosystem of vessels, immune cells, and connective tissu
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.